Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-060682
Filing Date
2023-11-08
Accepted
2023-11-08 07:29:45
Documents
61
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tngx-20230930.htm   iXBRL 10-Q 2255850
2 EX-31.1 tngx-ex31_1.htm EX-31.1 17394
3 EX-31.2 tngx-ex31_2.htm EX-31.2 17319
4 EX-32.1 tngx-ex32_1.htm EX-32.1 8237
5 EX-32.2 tngx-ex32_2.htm EX-32.2 8228
  Complete submission text file 0000950170-23-060682.txt   7614948

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tngx-20230930_cal.xml EX-101.CAL 43986
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tngx-20230930_pre.xml EX-101.PRE 258403
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tngx-20230930_lab.xml EX-101.LAB 360638
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tngx-20230930_def.xml EX-101.DEF 171439
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tngx-20230930.xsd EX-101.SCH 39375
55 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20230930_htm.xml XML 1414664
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39485 | Film No.: 231385956
SIC: 2834 Pharmaceutical Preparations